Spotlight On... Docs take aim at Novartis' 'horrifying' Entresto ad; U.K. cost gatekeepers shun Sanofi's PCSK9 drug but back Amgen's; BMS wins hep C label expansion for Daklinza; and more...

It's not often that a disease-awareness campaign makes unwanted waves. But Novartis' ($NVS) recently launched heart failure push is doing just that--literally and figuratively. More from FiercePharma

> U.K. cost watchdogs have backed Amgen's ($AMGN) PCSK9 contender, Repatha, but given Sanofi's ($SNY)--dubbed Praluent--a thumbs down. Report

> The FDA has green-lighted Bristol-Myers Squibb's ($BMY) Daklinza for more hard-to-treat hep C patients. Release

> Amid backlash for soaring drug prices, industry trade group PhRMA says it intends to spend several millions this year--10% more than in 2015--on digital, radio and print ads that highlight the industry's role in developing new treatments and advancing science. Report

> Cigna announced that it has entered into an outcomes-based contract with Novartis ($NVS) over heart-failure newcomer Entresto. More

Suggested Articles

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.

Gilead is working to move CAR-T med Yescarta into other types of NHL, and if data from an interim trial look-in are any indication, it's on its way.